Evaluation of PXL065 – deuterium-stabilized (R)-pioglitazone in patients with NASH: A phase II randomized placebo-controlled trial (DESTINY-1)
- 18 February 2023
- journal article
- research article
- Published by Elsevier in Journal of Hepatology
- Vol. 78 (5) , 914-925
Abstract
No abstract availableKeywords
This publication has 60 references indexed in Scilit:
- Thiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrierProceedings of the National Academy of Sciences, 2013
- Meta‐analysis: pioglitazone improves liver histology and fibrosis in patients with non‐alcoholic steatohepatitisAlimentary Pharmacology & Therapeutics, 2011
- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic SteatohepatitisNew England Journal of Medicine, 2010
- Importance of Changes in Adipose Tissue Insulin Resistance to Histological Response During Thiazolidinedione Treatment of Patients with Nonalcoholic Steatohepatitis†Hepatology, 2009
- Randomized, Placebo-Controlled Trial of Pioglitazone in Nondiabetic Subjects With Nonalcoholic SteatohepatitisGastroenterology, 2008
- The NAFLD fibrosis scoreHepatology, 2007
- Design and validation of a histological scoring system for nonalcoholic fatty liver disease†Hepatology, 2005
- Pioglitazone Prevents Early-Phase Hepatic Fibrogenesis Caused by Carbon TetrachlorideBiochemical and Biophysical Research Communications, 2002
- Expression and Characterization of Recombinant Rat Acyl-CoA Synthetases 1, 4, and 5Journal of Biological Chemistry, 2001
- Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.Diabetes Care, 2000